Introduction: There is evidence of the association of DNA methylation alterations with cancer
development and progression. Areas covered: This review will briefly discuss the basis of …

Introduction: DNA methylation is an epigenetic modification that modulates gene expression
without altering the DNA base sequence. It plays a crucial role in cancer by silencing tumor …

Gene silencing resulting from aberrant DNA methylation can lead to tumorigenesis.
Therefore, drugs that inhibit or interfere with DNA methylation have been used to reactivate …

Two nucleoside inhibitors of DNA methylation, azacitidine and decitabine, are now standard
of care for the treatment of the myelodysplastic syndrome, a deadly form of leukemia. These …

Dysregulation of cellular epigenetic machinery is linked to the pathogenesis of a number of
malignancies and has been studied extensively in myelodysplastic syndromes and acute …

DNA methyltransferase (DNMT) inhibitors, azacitidine (Vidaza®, Pharmion, Boulder, CO,
USA) and decitabine (Dacogen™; SuperGen Inc, Dublin, CA, USA, and MGI Pharma Inc …

DNA methylation represents a crucial mechanism of epigenetic regulation in hematologic
malignancies. The methylation process is controlled by specific DNA methyl transferases …

The myelodysplastic syndromes (MDS) are a group of hematologic disorders characterized
by ineffective hematopoiesis and increased risk of transformation to acute myeloid leukemia …

Epigenetics refers to partially reversible, somatically inheritable, but DNA sequence-
independent traits that modulate gene expression, chromatin structure, and cell functions …

DNA methyltransferase inhibitors (DNMTi) decitabine and azacytidine are approved
therapies for myelodysplastic syndrome and acute myeloid leukemia, and their …